Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  panobinostat
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
Ruxolitinib Phosphate and Panobinostat in Treating Patients with Myelofibrosis
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-1225, NCI-2017-00654, NCT01693601
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan before Stem Cell Transplant in Treating Patients with Refractory or Relapsed Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 2014-0516, NCI-2015-01308, NCT02506959
Panobinostat, Bortezomib, and Vincristine Sulfate Liposome with Re-induction Therapy in Treating Younger Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: TSALV, NCI-2015-00935, NCT02518750
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: MCC-18374, NCI-2016-00054, Novartis CLBH589BUS100T, NCT02588339
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLBH589D2222, NCI-2016-00234, NCT02654990
Panobinostat Maintenance Therapy in Treating Patients with Multiple Myeloma after Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18430, NCI-2016-00910, NCT02722941
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 74
Trial IDs: CLBH589DUS106, NCI-2016-01447, NCT02720510
Panobinostat, Cytarabine, and Daunorubicin Hydrochloride in treating Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Status: Active
Phase: Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 112512, NCI-2011-03532, NCT01463046
Panobinostat, Fludarabine Phosphate, and Cytarabine in Treating Younger Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 24 and under
Trial IDs: PANAML, NCI-2016-00098, NCT02676323
Panobinostat in Treating Younger Patients with Diffuse Intrinsic Pontine Glioma
Status: Active
Phase: Phase I
Type: Treatment
Age: 2 to 21
Trial IDs: PBTC-047, NCI-2015-01919, NCT02899715, NCT02717455
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2102, NCI-2016-01890, NCT02890069
Start Over